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Edited by Francesc PosasAbstract LEOPARD (LS) and Noonan (NS) are overlapping
syndromes associated with distinct mutations of SHP-2.
Whereas NS mutations enhance SHP-2 catalytic activity, we
show that the activity of three representative LS mutants is unde-
tectable when assayed using a standard protein tyrosine phospha-
tase (PTP) substrate. A diﬀerent assay using a speciﬁc SHP-2
substrate conﬁrms their decreased PTP activity, but also reveals
a signiﬁcant activity of the T468M mutant. In transfected cells
stimulated with epidermal growth factor, the least active LS mu-
tants promote Gab1/PI3K binding, validating our in vitro data.
LS mutants thus display a reduced PTP activity both in vitro
and in transfected cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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LEOPARD syndrome (multiple lentigines, electrocardio-
graphic conduction abnormalities, ocular hypertelorism,
pulmonary stenosis, abnormal genitalia, retardation of growth,
sensorineural deafness; LS; MIM#151100) is a rare genetic dis-
order characterized by multiple lentigines and other cutaneous
abnormalities such as ‘‘cafe´ au lait’’ spots, dysmorphic facies,
cardiac defects, growth retardation and increased risk of
malignancy. Several clinical manifestations overlap those of
Noonan syndrome (NS; MIM#163950), a common genetic
disease also typiﬁed by facial dysmorphy, heart defects and
growth retardation. However ‘‘cafe´ au lait’’ spots are rare
and multiple lentigines are typically absent in NS.
Recently, germline missense mutations in the PTPN11 gene
were identiﬁed in both syndromes and are now causally linkedAbbreviations: EGF, epidermal growth factor; IRS-1, insulin receptor
substrate 1; LS, LEOPARD syndrome; NS, Noonan syndrome; PTP,
protein tyrosine phosphatase; WT, wild type
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doi:10.1016/j.febslet.2006.03.088to the diseases [1,2]. Somatic PTPN11 mutations are also
responsible for juvenile myelomonocytic leukemia [3]. PTPN11
encodes SHP-2, awidely expressed protein tyrosine phosphatase
(PTP) involved in intracellular signalling downstream of several
growth factors, cytokines, and hormone receptors [4]. The struc-
ture of SHP-2 consists of two Src-homology 2 (SH2) domains
(N-SH2 and C-SH2), a single PTP domain and a C-terminal
hydrophilic tail. SHP-2 displays a low basal catalytic activity
due to close interactions between the N-SH2 and PTP domains
that keeps the phosphatase in an autoinhibited closed conforma-
tion. Its catalytic activation thus requires to open the molecule
by releasing these interactions, which occurs when its SH2 do-
mains bind to speciﬁc phosphotyrosine motifs on SHP-2 up-
stream signalling partners. These partners include the insulin
receptor substrate 1 (IRS-1) and the Grb2-associated binder 1,
Gab1. Both are adapter proteins rapidly phosphorylated in re-
sponse to the stimulation of insulin or epidermal growth factor
(EGF) receptors, respectively. Downstream of Gab1 or IRS-1,
SHP-2 promotes the activation of the Ras/mitogen-activated
pathway, through mechanisms that are still under investigation
[4,5]. Besides this signal-enhancing function, SHP-2 can play a
modulatory role in the activation of phosphoinositide 3-kinase
(PI3K), at least downstream of the EGF receptor. Indeed, this
receptor recruits PI3K by phosphorylating Gab1 on binding
sites for p85, the regulatory subunit of PI3K, and it was recently
shown that these sites are dephosphorylated by SHP-2 during
EGF stimulation [6].
In NS, most of SHP-2 mutations described so far aﬀect res-
idues located in or close to the interaction surface between the
N-SH2 and the PTP domains [7]. This is thought to disrupt the
autoinhibited closed conformation of SHP-2, resulting in an
increased basal PTP activity of most NS-associated SHP-2 mu-
tants observed in vitro [8,9]. Thus the basis of NS pathogenesis
is certainly due to activating, ‘‘gain-of-function’’ mutations of
SHP-2, even though the SHP-2-dependent mechanisms altered
by its NS-mutant derivatives remain to be identiﬁed. In LS,
only nine mutations were reported to date, aﬀecting seven dif-
ferent amino acids [7]. These residues are all located in the PTP
domain, and, even if no functional data were reported yet,
these mutations are predicted to be also ‘‘gain-of-function’’,
due to the clinical overlap between NS and LS.
Thiswork aimed to deﬁne the eﬀect of LSmutations on SHP-2
phosphatase activity. Using molecular modelling, all LS muta-
tions were strikingly located in the catalytic cleft of SHP-2. Weblished by Elsevier B.V. All rights reserved.
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representative LS mutations on SHP-2 catalytic activity.2. Materials and methods
2.1. Structural analysis of LS-associated SHP-2 mutant residues
The structure of wild-type (WT) SHP-2 [10] (PDB code 2shp) was
loaded into the program ICM (Molsoft LLC, www.molsoft.com)
and the LS-associated residues were mapped and visually inspected.2.2. Phosphopeptide synthesis
The substrate phosphopeptide Gab1-pY589 (DSEEN-pY-
VPMNPNL) and the activating peptide IRS1-pY1172 (SLN-pY-
IDLDLVK) [8] were synthesized using small-scale Fmoc chemistry.2.3. PTPN11 constructs
The human WT PTPN11 cDNA and the mutants D61Y and C459G
subcloned into the pcDNA6/V5-HisA vector were kindly provided by
Bruce D. Gelb. The NS-associated D61del mutation [11] and the LS-
associated mutations resulting in Y279C, T468M, and Q510P were
introduced using site-directed mutagenesis (QuickChange, Stratagene)
and veriﬁed by sequencing.2.4. Cell lines, transfections and stimulation
Vero cells were grown, transiently transfected and stimulated with
30 ng/ml EGF as described [5].2.5. Immune complex PTP assays
Transfected cells were harvested in lysis buﬀer: 25 mM HEPES, pH
7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100 and Protease
Inhibitor Cocktail (Sigma). SHP-2 was immunoprecipitated with
anti-V5 antibody (Invitrogen) then washed in lysis buﬀer and in PTP
buﬀer: 20 mM HEPES, pH 7.4, EDTA 1 mM, 5% glycerol, and
1 mM DTT. Immunocomplexes were resuspended in 50 ll of PTP buf-
fer supplemented with 250 lM of Src-pY529 phosphopeptide
(TSTEPQ-pY-QPGENL, Upstate Biotech) or 100 lM of Gab1-
pY589 phosphopeptide alone or with 10 lM of the activating peptide
IRS1-pY1172, and incubated for 30 min at 37 C. To assess free phos-
phate release, supernatants were then placed in 96-well plates with
Malachite Green solution (Upstate Biotech) and incubated for
15 min. Absorbances (630 nm) were compared to a phosphate stan-
dard curve [3,12].
2.6. GST-p85 aﬃnity precipitation assay
This was performed as described [5].3. Results and discussion
3.1. LS-associated SHP-2 mutated residues are clustered in the
PTP catalytic cleft
The nine missense mutations reported to date in LS aﬀect se-
ven diﬀerent amino acids localized exclusively in the SHP-2
PTP domain (Fig. 1A). To gain insight on LS mutations eﬀects
on SHP-2 function, we performed a structural model analysis
of the residues which are found mutated in LS with respect to
their positioning in the SHP-2 molecule [10]. Fig. 1B show that
the seven residues are highly clustered in the catalytic core of
the PTP domain, suggesting that LS mutations might alter
SHP-2 catalytic properties, rather than modify its activation
state as in the case of NS-associated mutations.
3.2. PTP activity of LS mutants is abolished when assayed using
a standard PTP substrate
To study the eﬀect of LS mutations on SHP-2 catalytic activ-
ity, we introduced by site-directed mutagenesis the mutationsgiving rise to the two common Y279C and T468M and the rare
Q510P single amino acid changes in a plasmid encoding hu-
man WT-SHP-2. After transfection of these constructs in
mammalian cells, we measured in vitro the catalytic activity
of each mutant isolated by immunoprecipitation. Vero cells
were chosen for their low basal level of SHP-2-dependent sig-
nalling pathways once incubated overnight in serum-free med-
ium [5,13]. Following immunoprecipitation, the PTP activity
of the diﬀerent constructs was assayed using as substrate a syn-
thetic phosphopeptide encompassing Y529 of Src, a standard
in vitro substrate of PTP [3,9]. To test these mutants under
stimulation by an upstream SHP-2 activator, the immunocom-
plexes were also incubated with 10 lM of a phosphopeptide
containing the SHP-2-binding site of IRS-1 (IRS1-pY1172)
[8]. As shown in Fig. 2, addition of IRS1-pY1172 phosphopep-
tide resulted in a 2–3-fold increase of WT-SHP-2 catalytic
activity, attesting that these experimental conditions allow to
detect SHP-2 activation. As additional controls, we veriﬁed
that the well-characterized catalytically dead C459G construct
displayed no PTP activity, and that the leukemia-associated
D61Y mutant and of the NS-associated D61del mutant have
an increased PTP activity compared to WT-SHP-2. These
two mutants are not signiﬁcantly overstimulated by the
IRS1-pY1172 peptide in these conditions, but this is in agree-
ment with a previous report [8]. In addition, when the immu-
nocomplexes were incubated with the activating peptide
alone, the release of phosphate was undetectable for any of
SHP-2 construct (data not shown), indicating that this phos-
phopeptide was not signiﬁcantly dephosphorylated by SHP-2
when used in these conditions appropriate to observe its acti-
vating eﬀect. This series of controls validated the methodology
used in this study.
More interestingly, when considering the three LS-associ-
ated SHP-2 mutants, Fig. 2 shows that their basal catalytic
activity is similar to that of the catalytically dead C459G con-
struct. In the presence of the activating peptide, a slight but
signiﬁcant increase of PTP activity was detected in the case
of Y279C and T468M mutants, but this activity remains at
the most around 10% of that of WT-SHP-2. Taken together,
these results suggest that LS mutations lead to the loss of
SHP-2 catalytic activity, probably by disruption of the integ-
rity of SHP-2 catalytic cleft.3.3. PTP assay of LS mutants using a speciﬁc SHP-2 substrate
conﬁrms their decreased activity but reveals a signiﬁcant
activity of T468M mutant
The above results were obtained with a standard PTP sub-
strate, which is not considered as an undeniable SHP-2 sub-
strate in vivo. We thus determined if LS mutations had the
same eﬀect on SHP-2 catalytic activity when assayed on a
validated SHP-2 substrate. To this aim, we designed a phos-
phopeptide encompassing Y589 of Gab1 (Gab1-pY589 phos-
phopeptide), which corresponds to a PI3K-binding site and
is known to be dephosphorylated by SHP-2 in cells treated
with EGF [6]. As shown in Fig. 3, the basal PTP activity of
the three LS mutants assayed with this peptide is still severely
reduced in comparison with the WT protein. However, in the
case of the T468M mutant, its basal activity is around 30%
of that of WT-SHP-2. Under stimulation with IRS1-pY1172,
the Q510P mutant still displayed a negligible PTP activity. In
contrast, the two other mutants seem to display a signiﬁcant
Fig. 1. LS-associated SHP-2 mutated residues are clustered in the PTP domain of the protein. (A) Schematic representation of SHP-2 showing the
distribution of mutations identiﬁed in LS (above). Position of hyperactive and inactive SHP-2 mutants studied in this report are also indicated
(below). (B) Left: ribbon representation of SHP-2 structure in its autoinhibited closed conformation [10]. The N- and C-terminal SH2 domains are
coloured in yellow and green, respectively, the catalytic domain in blue. The red square depicts the closeup region. Right: Close-up of the active site
and location of LS-associated SHP-2 mutated residues. The two most frequently altered residues Y279 and T468 are represented as orange sticks,
while other mutations are shown as magenta sticks. Position of D61 (on the inhibitory loop of N-SH2 domain protruding into the catalytic site)
responsible for autoinhibition of PTP activity is highlighted in red.
Fig. 2. PTP activity of LS mutants is abolished when assayed using a standard PTP substrate. Immune complex PTP assay against 250 lM Src-
pY529 with or without 10 lM activating peptide IRS1-pY1172 carried out on serum-starved Vero cells transfected with the indicated SHP-2
construct. Bottom: representative anti-V5 immunoblots of immunoprecipitates. NT, experiments performed from non-transfected cells. Data
represent means ± S.D. from three independent experiments. Signiﬁcant diﬀerences in PTP activity between basal and activated conditions are
indicated (*P < 0.05, ***P < 0.001).
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Fig. 3. PTP assays of LS mutants using a speciﬁc SHP-2 substrate. Immune complex PTP assays against 100 lM Gab1-pY589 with or without
activating peptide IRS1-pY1172 carried out on serum-starved Vero cell transfected with the indicated SHP-2 construct. Bottom: representative anti-
V5 immunoblot of immunoprecipitates. NT, experiments performed from non-transfected cells. Data represent means ± S.D. from three independent
experiments. *, diﬀerent from condition without IRS1-pY1172, P < 0.05.
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SHP-2. These results thus conﬁrm the Fig. 2 data showing that
LS mutations, in contrast with NS mutations, lead to a de-
crease in SHP-2 catalytic activity. However, these experiments
also indicate that diﬀerent LS mutations produce distinct levels
of alteration of SHP-2 activity, which was not detected using a
standard PTP substrate. This suggest that at least one LS
mutation inﬂuences SHP-2 substrate recognition rather than
suppresses its catalytic activity.
3.4. In situ conﬁrmation of in vitro assays: the least active LS
mutants promote Gab1/PI3K binding in EGF-stimulated
cells
We next determined whether these in vitro features of LS
mutants could be conﬁrmed in transfected cells, by testing
the eﬀects of these mutants on the dephosphorylation of a
cellular substrate of SHP-2. Because SHP-2 can dephosphor-
ylate Gab1 on its PI3K-binding sites in response to EGF [6],
we designed an experiment to monitor these sites phosphor-
ylation. Vero cells were chosen again, since they can be eﬃ-
ciently stimulated by EGF, leading to the phosphorylation
of Gab1 and the downstream activation of SHP-2 and
PI3K [5,13]. Following stimulation with EGF, cells were
incubated with a GST-p85 fusion protein, which allows to
precipitate Gab1 only if phosphorylated on PI3K binding
sites [5,13]. As positive control, in cells transfected with cat-
alytically dead C459G SHP-2, GST-p85 precipitates an high-
er amount of Gab1 in comparison with WT SHP-2,
whereas, as negative control, the hyperactive D61del mutant
prevents Gab1 precipitation (Fig. 4A–C, compare lanes
‘‘C459G’’ and ‘‘D61del’’ with ‘‘WT’’). Thus Gab1 amount
precipitated with GST-p85 appears inversely proportional
to SHP-2 catalytic activity, showing that the Gab1/PI3K
interaction can be taken as marker of the cellular catalytic
activity of SHP-2.
Once validated, this assay was applied to cells expressing LS
mutants. The results show that the Y279C and Q510P mutants
enhance, compare to the WT-SHP-2, Gab1 recovery in GST-
p85 pulldowns, measured either after 5 or 10 min of EGF stim-
ulation (Fig. 4A and B). A quantitative analysis of data from
diﬀerent experiments indicates that these mutants produce an
eﬀect similar to that of catalytically dead SHP-2 C459G
(Fig. 4D). In contrast, the T468M mutant did not enhance
Gab1 precipitation by GST-p85 in comparison with WT-SHP-2, implying that this mutant species retains some of its
phosphatase activity towards Gab1 PI3K-binding sites
(Fig. 4C and D). We conclude that the LS mutants Y279C
and Q510P behave in situ like catalytically inactive mutants,
which conﬁrms our in vitro data showing that these mutants
display the lowest PTP activity. In addition, the fact that the
T468M mutant does not promote Gab1/PI3K interaction
more than the WT protein also conﬁrms the in vitro results
since this mutation was found to reduce, but not to abolish,
its catalytic activity on Gab1 phosphopeptide. It is thus likely
that this mutation does alter the catalytic eﬃciency of the
T468M mutant, but its residual activity appears suﬃcient to
dephosphorylate Gab1 in EGF-stimulated cells.
The apparent lack of hyperactivity of D61 mutants in vitro
on Gab1-pY589 substrate is probably due to the use of a con-
centration of Gab1-pY589 lower than that of Src-pY529 phos-
phopeptide, according to previous reports that utilized these
substrates [3,12], which likely results in a more rapid substrate
depletion of Gab1-pY589. In support of this view, the experi-
ments in intact cells (Fig. 4) show that the D61del mutant dis-
plays hyperactivity toward Gab1 PI3K-binding sites, which
include Y589.
During the preparation of this manuscript, it was reported
that LS-associated SHP-2 mutants, including Y279C and
T468M, have lost their catalytic activity when assayed on stan-
dard PTP substrates [14]. The data obtained from our experi-
ments performed in identical conditions conﬁrm these
observations. However, we measured for the ﬁrst time the
PTP activity of LS mutants using a speciﬁc SHP-2 substrate.
At least in the case of the T468M mutant, we were able to de-
tect a signiﬁcant PTP activity, an observation which was vali-
dated ex vivo by monitoring Gab1/PI3K interaction. This
reveals the importance of substrate choice for in vitro measure-
ments of SHP-2 catalytic activity.
In conclusion, in contrast to NS, LS-associated SHP-2 mu-
tants display a reduced PTP activity. How these apparently
opposite behaviours of SHP-2 mutants lead to clinically over-
lapped syndromes still remain to be explained. However, the
observation that one mutation (T468M) might possibly alter
the substrate speciﬁcity of SHP-2 suggests that an heterogene-
ity of biochemical features exists between the diﬀerent mu-
tants, which may well be the key to the understanding of the
variable occurrence of the diﬀerent symptoms associated to
each of these syndromes.
Fig. 4. Inactive LS mutants promote Gab1/PI3K binding in EGF-stimulated cells. (A–C) Vero cells cotransfected with Myc-tagged WT Gab1 and
the indicated V5-tagged SHP-2 construct were stimulated with EGF when indicated. Cleared lysates were then subjected to a p85 aﬃnity
precipitation assay (‘‘pulldown’’) using a GST-p85a fusion protein. The amount of Gab1-Myc precipitated with GST-p85a has analysed by anti-Myc
immunoblotting (top panels). Corresponding lysates were subjected to anti-Myc (middle panels) and anti-V5 (bottom panels) immunoblotting. (D)
The immunoblots from three independent GST-p85 pulldown experiments were quantiﬁed using the software ImageQuant (Molecular Dynamics).
Data represent means ± S.D. from three independent experiments. ***, diﬀerent from WT (EGF 5 min), P < 0.001.
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